(Circulation. 1999;100:21-26.)
© 1999 American Heart Association, Inc.
Clinical Investigation and Reports |
Impact of Cilostazol on Restenosis After Percutaneous Coronary Balloon Angioplasty
From the Department of Cardiology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.
Correspondence to Etsuo Tsuchikane, MD, The Department of Cardiology, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1-3-3, Nakamichi, Higashinari, Osaka-City, Osaka, 537-1181 Japan. E-mail oscmed1{at}skyblue.ocn.ne.jp
Background—Restenosis after percutaneous transluminal coronary (balloon) angioplasty (PTCA) remains a major drawback of the procedure. We previously reported that cilostazol, a platelet aggregation inhibitor, inhibited intimal proliferation after directional coronary atherectomy and reduced the restenosis rate in humans. The present study aimed to determine the effect of cilostazol on restenosis after PTCA.
Methods and Results—Two hundred eleven patients with 273 lesions who underwent successful PTCA were randomly assigned to the cilostazol (200 mg/d) group or the aspirin (250 mg/d) control group. Administration of cilostazol was initiated immediately after PTCA and continued for 3 months of follow-up. Quantitative coronary angiography was performed before PTCA and after PTCA and at follow-up. Reference diameter, minimal lumen diameter, and percent diameter stenosis (DS) were measured by quantitative coronary angiography. Angiographic restenosis was defined as DS at follow-up >50%. Eligible follow-up angiography was performed in 94 patients with 123 lesions in the cilostazol group and in 99 patients with 129 lesions in the control group. The baseline characteristics and results of PTCA showed no significant difference between the 2 groups. However, minimal lumen diameter at follow-up was significantly larger (1.65±0.55 vs 1.37±0.58 mm; P<0.0001) and DS was significantly lower (34.1±17.8% vs 45.6±19.3%; P<0.0001) in the cilostazol group. Restenosis and target lesion revascularization rates were also significantly lower in the cilostazol group (17.9% vs 39.5%; P<0.001 and 11.4% vs 28.7%; P<0.001).
Conclusions—Cilostazol significantly reduces restenosis and target lesion revascularization rates after successful PTCA.
Key Words: platelet aggregation inhibitors • restenosis • angioplasty
This article has been cited by other articles:
 |
|
 |
|
  K.-Y. Chen, S.-W. Rha, Y.-J. Li, K. L. Poddar, Z. Jin, Y. Minami, L. Wang, E. J. Kim, C. G. Park, H. S. Seo, et al. Triple Versus Dual Antiplatelet Therapy in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention Circulation, June 30, 2009; 119(25): 3207 - 3214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ishii, Y. Kumada, T. Toriyama, T. Aoyama, H. Takahashi, S. Yamada, Y. Yasuda, Y. Yuzawa, S. Maruyama, S. Matsuo, et al. Cilostazol Improves Long-Term Patency after Percutaneous Transluminal Angioplasty in Hemodialysis Patients with Peripheral Artery Disease Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1034 - 1040. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Becker, T. W. Meade, P. B. Berger, M. Ezekowitz, C. M. O'Connor, D. A. Vorchheimer, G. H. Guyatt, D. B. Mark, and R. A. Harrington The Primary and Secondary Prevention of Coronary Artery Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 776S - 814S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Meadows and D. L. Bhatt Clinical Aspects of Platelet Inhibitors and Thrombus Formation Circ. Res., May 11, 2007; 100(9): 1261 - 1275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Douglas Jr, D. R. Holmes Jr, D. J. Kereiakes, C. L. Grines, E. Block, Z. M.B. Ghazzal, D. C. Morris, H. Liberman, K. Parker, C. Jurkovitz, et al. Coronary Stent Restenosis in Patients Treated With Cilostazol Circulation, November 1, 2005; 112(18): 2826 - 2832. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. E. Sumpio and J. Aruny Cilostazol Inhibits Leukocyte Integrin Mac-1, Leading to a Potential Reduction in Restenosis After Coronary Stent Implantation Perspectives in Vascular Surgery and Endovascular Therapy, September 1, 2005; 17(3): 265 - 267. [Abstract] [PDF]
|
|
|
|
 |
|
 M.-J. Kim, K.-G. Park, K.-M. Lee, H.-S. Kim, S.-Y. Kim, C.-S. Kim, S.-L. Lee, Y.-C. Chang, J.-Y. Park, K.-U. Lee, et al. Cilostazol Inhibits Vascular Smooth Muscle Cell Growth by Downregulation of the Transcription Factor E2F Hypertension, April 1, 2005; 45(4): 552 - 556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Popma, P. Berger, E. M. Ohman, R. A. Harrington, C. Grines, and J. I. Weitz Antithrombotic Therapy During Percutaneous Coronary Intervention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 576S - 599S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. N. Babapulle and M. J. Eisenberg Coated Stents for the Prevention of Restenosis: Part I Circulation, November 19, 2002; 106(21): 2734 - 2740. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Schnyder, M. Roffi, Y. Flammer, R. Pin, and O.M. Hess Association of plasma homocysteine with restenosis after percutaneous coronary angioplasty Eur. Heart J., May 1, 2002; 23(9): 726 - 733. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Schnyder, M. Roffi, R. Pin, Y. Flammer, H. Lange, F. R. Eberli, B. Meier, Z. G. Turi, and O. M. Hess Decreased Rate of Coronary Restenosis after Lowering of Plasma Homocysteine Levels N. Engl. J. Med., November 29, 2001; 345(22): 1593 - 1600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-W. Park, M.-K. Hong, D. H. Moon, S. J. Oh, C. W. Lee, J.-J. Kim, and S.-J. Park Treatment of diffuse in-stent restenosis with rotational atherectomy followed by radiation therapy with a rhenium-188-mercaptoacetyltriglycine-filled balloon J. Am. Coll. Cardiol., September 1, 2001; 38(3): 631 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. R. Hiatt Medical Treatment of Peripheral Arterial Disease and Claudication N. Engl. J. Med., May 24, 2001; 344(21): 1608 - 1621. [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Osinski, B. H. Rauch, and K. Schrör Antimitogenic Actions of Organic Nitrates Are Potentiated by Sildenafil and Mediated Via Activation of Protein Kinase A Mol. Pharmacol., April 16, 2001; 59(5): 1044 - 1050. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. S Ettenson and E. R Edelman Local drug delivery: an emerging approach in the treatment of restenosis Vascular Medicine, May 1, 2000; 5(2): 97 - 102. [Abstract] [PDF]
|
|
|
|
|
|
B. Chandrasekar and J.-F. Tanguay Platelets and restenosis J. Am. Coll. Cardiol., March 1, 2000; 35(3): 555 - 562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-i. Hayashi, R. Morishita, H. Matsushita, H. Nakagami, Y. Taniyama, T. Nakamura, M. Aoki, K. Yamamoto, J. Higaki, and T. Ogihara Cyclic AMP Inhibited Proliferation of Human Aortic Vascular Smooth Muscle Cells, Accompanied by Induction of p53 and p21 Hypertension, January 1, 2000; 35(1): 237 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Cilostazol Reduces Restenosis After PTCA Journal Watch Cardiology, September 16, 1999; 1999(916): 5 - 5. [Full Text]
|
|